Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 559
Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis
Y J Youn, Seung Yeon Kim, Hyun‐Jeong Jeong, et al.
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101131-101131
Open Access | Times Cited: 20
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 18
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study
Anna Shin, Bo Kyung Koo, Jun Young Lee, et al.
BMJ (2024), pp. e079475-e079475
Open Access | Times Cited: 16
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis
Bo Xu, Mingxia Yang, Shaoqian Li, et al.
Annals of Pharmacotherapy (2025)
Closed Access | Times Cited: 2
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis
Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 441-462
Open Access | Times Cited: 31
Risk of Dementia in Patients with Diabetes Using Sodium-Glucose Transporter 2 Inhibitors (SGLT2i): A Systematic Review, Meta-Analysis, and Meta-Regression
Pricilla Yani Gunawan, Paskalis Andrew Gunawan, Timotius Ivan Hariyanto
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 663-675
Open Access | Times Cited: 11
The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation
Yun‐Yu Chen, Hao‐Chih Chang, Yenn‐Jiang Lin, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 2
Open Access | Times Cited: 11
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101623-101623
Closed Access | Times Cited: 1
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study
Yu‐Yu Hsiao, Yun‐Yu Chen, Ming‐Jen Kuo, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access | Times Cited: 1
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
Adelene Y. L. Sim, Da Hyun Choi, Jong Youl Kim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115755-115755
Open Access | Times Cited: 17
Heterogeneous treatment effects of sodium‐glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population‐based cohort study
Huilin Tang, William T. Donahoo, Mikael Svensson, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5528-5539
Open Access | Times Cited: 8
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Jacky Tran, Sneh Parekh, Julia Rockcole, et al.
Life Sciences (2024) Vol. 355, pp. 123001-123001
Closed Access | Times Cited: 8
Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks
Yen‐Wei Pai, I‐Chieh Chen, Jun‐Fu Lin, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 8
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jiang, Ji Li, Xiaohui Yao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
SGLT inhibitors for improving Healthspan and lifespan
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 16
Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
Ronald R. Grunstein, Thomas A. Wadden, Julia L. Chapman, et al.
SLEEP (2023) Vol. 46, Iss. 10
Open Access | Times Cited: 13
Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
Flora Affuso, Filomena Micillo, Sergio Fazio
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1888-1888
Open Access | Times Cited: 5
Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment in Individuals with Type 2 Diabetes
Anu Gupta, Alpesh Goyal, Roopa Rajan, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1155-1168
Open Access | Times Cited: 4
Cognitive dysfunction in diabetes – the ‘forgotten’ diabetes complication: a narrative review
Åke Sjöholm, Louise Bennet, Peter M. Nilsson
Scandinavian Journal of Primary Health Care (2025), pp. 1-7
Open Access
Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study
Pei-Chun Chiang, Cheng-Yang Hsieh, Sheng‐Feng Sung
Journal of Stroke and Cerebrovascular Diseases (2025), pp. 108276-108276
Open Access
Diabetes Mellitus and Cognitive Decline: A Systematic Review Exploring the Link to Dementia and Neurodegenerative Diseases
Abdul Khaliq, Aroon Kumar, Mahnoor Khan, et al.
Cureus (2025)
Open Access
Page 1 - Next Page

Scroll to top